Jasper Therapeutics, Inc. (JSPR)
Last updated: 2026-10-28 19:18:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Jasper Therapeutics, Inc. (JSPR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.53, with a market capitalization of $16.82M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.32 to $2.52. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$16.82M | |
$0.50 | |
$188.80 | |
$0.32 | |
$0.52 | |
335.86K | |
501.86K | |
-- | |
$2.52 | |
$0.32 | |
-- | |
-- |
Jasper Therapeutics, Inc. (JSPR) Stock Price Today
Jasper Therapeutics, Inc. (JSPR) is currently trading at $0.53 as of 2026-10-28 19:17:00, up 1.95% ($0.01) from the previous close of $0.52
During today's regular trading session, JSPR has traded between $0.32 and $188.80, with a trading volume of 335.86K shares. The current price is near the lower end of today's range.
Jasper Therapeutics, Inc. (JSPR) 7-Day Stock Price Change
Over the past seven days, Jasper Therapeutics, Inc. (JSPR) moved from $0.48 to $0.53, representing a gain of 10.81% ($0.05).
The stock traded between $0.46 and $0.61 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 462.00 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
JSPR 52-Week Price Position
Position in Range: 9.7%
JSPR is currently trading at $0.53, placing it 9.7% of the way from its 52-week low of $0.32 to its 52-week high of $2.52. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Jasper Therapeutics, Inc. (JSPR)?
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Jasper Therapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 22 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Jasper Therapeutics, Inc. (JSPR) Stock on MEXC
Eligible investors can buy real shares of Jasper Therapeutics, Inc. (JSPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Jasper Therapeutics, Inc. (JSPR) stock price today?
2.Is JSPR stock going up or down today?
3.What is JSPR pre-market price?
4.What is JSPR after-hours price?
5.Is JSPR stock trading now?
6.Where does JSPR sit relative to its 52-week high and low?
7.What sector is Jasper Therapeutics, Inc. in?
8.What is Jasper Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is JSPR valued in terms of P/E ratio and EPS?
10.Does Jasper Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
JSPR Stock Calculator
Estimate the value between JSPR shares and USD.
JSPR Shares to USD
1.00 JSPR shares = 0.529 USD
Calculations are estimates based on the latest available price and are for reference only.


